Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Raw Materials (2025 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Raw Materials for 2 consecutive years, with $30.7 million as the latest value for Q1 2026.

  • For Q1 2026, Raw Materials rose 1661.04% year-over-year to $30.7 million; the TTM value through Mar 2026 reached $30.7 million, up 1661.04%, while the annual FY2025 figure was $29.0 million, N/A changed from the prior year.
  • Raw Materials hit $30.7 million in Q1 2026 for Syndax Pharmaceuticals, up from $29.0 million in the prior quarter.
  • Across five years, Raw Materials topped out at $30.7 million in Q1 2026 and bottomed at $1.7 million in Q1 2025.